SAGE Therapeutics Inc (NASDAQ:SAGE) – Investment analysts at SunTrust Banks issued their FY2022 earnings per share estimates for SAGE Therapeutics in a report issued on Tuesday. SunTrust Banks analyst E. Nash anticipates that the biopharmaceutical company will post earnings of $2.52 per share for the year. SunTrust Banks currently has a “Buy” rating and a $203.00 price target on the stock.
Other equities research analysts have also recently issued reports about the company. Leerink Swann upped their target price on SAGE Therapeutics from $123.00 to $246.00 in a research note on Thursday, December 7th. Royal Bank of Canada upped their price target on shares of SAGE Therapeutics from $117.00 to $120.00 in a report on Thursday, November 2nd. Bank of America lowered their price target on shares of SAGE Therapeutics from $103.00 to $101.00 and set a “buy” rating for the company in a report on Thursday, November 16th. Needham & Company LLC upped their price target on shares of SAGE Therapeutics from $86.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Finally, Chardan Capital upgraded shares of SAGE Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $140.00 in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $176.47.
SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, topping the consensus estimate of ($1.98) by $0.23. During the same period in the prior year, the firm earned ($1.50) EPS.
A number of hedge funds and other institutional investors have recently bought and sold shares of SAGE. New York State Common Retirement Fund grew its holdings in SAGE Therapeutics by 258.0% during the 3rd quarter. New York State Common Retirement Fund now owns 149,564 shares of the biopharmaceutical company’s stock worth $9,318,000 after acquiring an additional 107,782 shares during the period. American Century Companies Inc. grew its holdings in SAGE Therapeutics by 8.4% during the 3rd quarter. American Century Companies Inc. now owns 25,343 shares of the biopharmaceutical company’s stock worth $1,579,000 after acquiring an additional 1,959 shares during the period. Bank of New York Mellon Corp grew its holdings in SAGE Therapeutics by 36.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock worth $168,834,000 after acquiring an additional 724,494 shares during the period. Jane Street Group LLC acquired a new stake in SAGE Therapeutics during the 3rd quarter worth about $817,000. Finally, Stifel Financial Corp acquired a new stake in SAGE Therapeutics during the 2nd quarter worth about $401,000. Institutional investors and hedge funds own 87.33% of the company’s stock.
In related news, insider Stephen Kanes sold 44,000 shares of the stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $177.18, for a total value of $7,795,920.00. Following the completion of the sale, the insider now directly owns 46,348 shares in the company, valued at $8,211,938.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $157.45, for a total value of $33,103,390.15. Following the completion of the sale, the chief executive officer now owns 211,473 shares of the company’s stock, valued at $33,296,423.85. The disclosure for this sale can be found here. Insiders sold 314,247 shares of company stock valued at $50,465,110 over the last 90 days. 6.10% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “SunTrust Banks Comments on SAGE Therapeutics Inc’s FY2022 Earnings (SAGE)” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3231071/suntrust-banks-comments-on-sage-therapeutics-incs-fy2022-earnings-sage.html.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.